Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Efficacy And Safety Of Trastuzumab As A Single Agent In First-line Treatment Of HER2-overexpressing Metastatic Breast Cancer.

C. Vogel, M. Cobleigh, D. Tripathy, J. Gutheil, L. Harris, L. Fehrenbacher, D. Slamon, M. Murphy, W. Novotny, M. Burchmore, S. Shak, S. Stewart, M. Press
Published 2002 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
PURPOSE To evaluate the efficacy and safety of first-line, single-agent trastuzumab in women with HER2-overexpressing metastatic breast cancer. PATIENTS AND METHODS One hundred fourteen women with HER2-overexpressing metastatic breast cancer were randomized to receive first-line treatment with trastuzumab 4 mg/kg loading dose, followed by 2 mg/kg weekly, or a higher 8 mg/kg loading dose, followed by 4 mg/kg weekly. RESULTS The objective response rate was 26% (95% confidence interval [CI], 18.2% to 34.4%), with seven complete and 23 partial responses. Response rates in 111 assessable patients with 3+ and 2+ HER2 overexpression by immunohistochemistry (IHC) were 35% (95% CI, 24.4% to 44.7%) and none (95% CI, 0% to 15.5%), respectively. The clinical benefit rates in assessable patients with 3+ and 2+ HER2 overexpression were 48% and 7%, respectively. The response rates in 108 assessable patients with and without HER2 gene amplification by fluorescence in situ hybridization (FISH) analysis were 34% (95% CI, 23.9% to 45.7%) and 7% (95% CI, 0.8% to 22.8%), respectively. Seventeen (57%) of 30 patients with an objective response and 22 (51%) of 43 patients with clinical benefit had not experienced disease progression at follow-up at 12 months or later. The most common treatment-related adverse events were chills (25% of patients), asthenia (23%), fever (22%), pain (18%), and nausea (14%). Cardiac dysfunction occurred in two patients (2%); both had histories of cardiac disease and did not require additional intervention after discontinuation of trastuzumab. There was no clear evidence of a dose-response relationship for response, survival, or adverse events. CONCLUSION Single-agent trastuzumab is active and well tolerated as first-line treatment of women with metastatic breast cancer with HER2 3+ overexpression by IHC or gene amplification by FISH.
This paper references
First line, non-hormonal treatment of women with HER2 overexpressing metastatic breast cancer with herceptin (trastuzumab, humanized anti-HER2 antibody)
C. Vogel (2000)
The biology of erbB-2/neu/HER-2 and its role in cancer.
N. E. Hynes (1994)
Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.
D. Slamon (1989)
The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology.
N. Aaronson (1993)
The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: a paradigm for the development of other macromolecular markers--a review.
P. Ravdin (1995)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
D. Slamon (2001)
c-erbB-2 oncoprotein expression in primary and advanced breast cancer.
C. Lovekin (1991)
Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease.
M. Cobleigh (1999)
Humanization of an anti-p185HER2 antibody for human cancer therapy.
P. Carter (1992)
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.
D. Slamon (1987)

This paper is referenced by
CDC25A protein stability represents a previously unrecognized target of HER2 signaling in human breast cancer: implication for a potential clinical relevance in trastuzumab treatment.
Emanuela Brunetto (2013)
Foroogh Nejatollahi (2008)
À la recherche des patientes présentant un cancer HER2/neu positif : analyse rétrospective
O. Blaizel (2006)
Refinement of Immunohistologic Parameters for Her2/neu Scoring Validation by FISH and CISH
A. Leong (2006)
Dissecting GRB 7-mediated signals for proliferation and migration in HER 2 overexpressing breast tumor cells : GTPase rules
De Pradip (2013)
Utilisation du virus de la rougeole en virothérapie anti-tumorale
N. Boisgerault (2011)
Evaluation of HER-2/neu gene amplification by fluorescence in situ hybridization and immunohistochemistry in saudi female breast cancer.
Heba Al-Khattabi (2010)
FISH and chips: a review of microfluidic platforms for FISH analysis
Pablo Rodriguez-Mateos (2020)
Trastuzumab in combination with heregulin-activated Her-2 (erbB-2) triggers a receptor-enhanced chemosensitivity effect in the absence of Her-2 overexpression.
J. Menéndez (2006)
The role of epidermal growth factor receptor in advanced non‐small cell lung carcinoma
P. Jänne (2003)
Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831.
P. Roche (2002)
Therapeutic Antibodies in Cancer Therapy.
M. Gasser (2016)
PRKACA Mediates Resistance to HER2-Targeted Therapy in Breast Cancer Cells and Restores Anti-Apoptotic Signaling
S. Moody (2014)
NOTCH1 activation in breast cancer confers sensitivity to inhibition of SUMOylation
M. Licciardello (2014)
Targeting HER-2 Signaling Network: Implication in Radiation Response
I. Kim (2011)
Tumor-targeting anti-EGFR x anti-PD1 bispecific antibody inhibits EGFR-overexpressing tumor growth by combining EGFR blockade and immune activation with direct tumor cell killing
L. Li (2020)
Trastuzumab signaling in ErbB2-overexpressing inflammatory breast cancer correlates with X-linked inhibitor of apoptosis protein expression
K. Aird (2008)
Trastuzumab in the treatment of early-stage breast cancer
K. Jones (2006)
Traitements médicaux guidés par la biologie en pathologie mammaire
N. Berrada (2010)
Challenges in the clinical utility of the serum test for HER2 ECD.
L. Lam (2012)
Advanced research on neoadjuvant therapy with trastuzumab in HER2-positive breast cancer
J. Liu (2014)
Clinical implications of the cancer genome.
L. Macconaill (2010)
mTOR Inhibitors in Cancer Treatment
Leonidas C. Platanias (2011)
[Personalized medicine and individual healthcare : Medical and information technology aspects].
W. Niederlag (2010)
8. Cancer Drugs
Narendra Bhalchandra Ambhaikar (2013)
Trastuzumab and chemotherapy after the treatment failure of lapatinib for HER2-positive metastatic breast cancer.
Y. Suzuki (2010)
Novel sorafenib analogues induce apoptosis through SHP-1 dependent STAT3 inactivation in human breast cancer cells
C. Liu (2012)
Fusogenic membrane glycoproteins as a gene therapy for cancer.
Bateman Ar (2003)
Health care outcomes of the various treatment methods of breast cancer in Node-Positive Premenopausal Women with Breast Cancer
Ahmed Alghamdi (2016)
Development of nanoparticle platform for therapeutic siRNA and drug delivery to breast cancer
Worapol Ngamcherdtrakul (2015)
BiHC, a T-Cell–Engaging Bispecific Recombinant Antibody, Has Potent Cytotoxic Activity Against Her2 Tumor Cells1
Jieyu Xing (2017)
SRSF 3 and hnRNP H 1 regulate a splicing hotspot of HER 2 in breast cancer cells
H. Gautrey (2015)
See more
Semantic Scholar Logo Some data provided by SemanticScholar